Immunovant Inc expected to post a loss of 38  cents a share - Earnings Preview

Immunovant

27/05/2022 14:17

* Immunovant Inc  IMVT.OQ   IMVT.O  is expected to show no
change
in quarterly revenue when it reports  results on May 30
(estimated). 
    * ​Refinitiv's mean analyst estimate for Immunovant Inc is
for a
loss of 38 cents per share. For the same quarter last year, the
company reported a loss of 29 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Immunovant
Inc is
$12​, above​ its last closing price of $4.02. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.32       -0.33      -0.36     Missed  -9.9
 Sep. 30 2021  -0.26       -0.28      -0.35     Missed  -25
 Jun. 30 2021  -0.31       -0.31      -0.31     Met     0​
 Mar. 31 2021  -0.33       -0.33      -0.29     Beat    12.9
 ​​Dec.        -0.25       -0.26      -0.32     Missed  -24.1
 31 2020                                                
 Sep. 30 2020  -0.35       -0.34      -0.25     Beat    26.5​
 Jun. 30 2020  -0.33       -0.33      -0.38     Missed  -15.9
 Mar. 31 2020  -0.53       -0.41      -0.38     Beat    7.7
 This summary was machine generated May 27 at 13:17 GMT.  All
figures in US dollars  unless otherwise stated